Science & Technology
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AI174482-01
Award Ceiling
$600K
Award Floor
$600K
Close Date
Feb 28, 2025
Total Funding
$600K
Expected Awards
1
Posted Date
Mar 1, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AI174482-01
Description
SBIR Phase Phase I award: "FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections" awarded to FIMBRION THERAPEUTICS INC in SAINT LOUIS, Missouri. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $600,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.